key: cord-0980114-22gzdwud authors: Sanchez, Antonio O.; Ochoa, Anna R.; Hall, Sallie L.; Voelker, Chet R.; Mahoney, Rachel E.; McDaniel, Jennifer S.; Blackburn, August; Asin, Susana N.; Yuan, Tony T. title: Comparison of next generation diagnostic systems (NGDS) for the detection of SARS‐CoV‐2 date: 2022-02-17 journal: J Clin Lab Anal DOI: 10.1002/jcla.24285 sha: beb52f9bc755b0f62666060db3d9ad76dc5a6916 doc_id: 980114 cord_uid: 22gzdwud INTRODUCTION: The World Health Organization (WHO) declared coronavirus disease 2019 (COVID‐19) a pandemic in March 2020. Initially, supply chain disruptions and increased demand for testing led to shortages of critical laboratory reagents and inadequate testing capacity. Thus, alternative means of biosample collection and testing were essential to overcome these obstacles and reduce viral transmission. This study aimed to 1) compare the sensitivity and specificity of Cepheid GeneXpert(®) IV and BioFire(®) FilmArray(®) 2.0 next generation detection systems to detect SARS‐CoV‐2, 2) evaluate the performance of both platforms using different biospecimen types, and 3) assess saline as an alternative to viral transport media (VTM) for sample collection. METHODS: A total of 1,080 specimens consisting of nasopharyngeal (NP) swabs in VTM, NP swabs in saline, nasal swabs, oropharyngeal (OP) swabs, and saliva were collected from 216 enrollees. Limit of detection (LoD) assays, NP VTM and NP saline concordance, and saliva testing were performed on the BioFire(®) FilmArray(®) 2.0 Respiratory Panel 2.1 and Cepheid GeneXpert(®) Xpress SARS‐CoV‐2/Flu/RSV assays. RESULTS: LoD and comparative testing demonstrated increased sensitivity with the Cepheid compared with the BioFire(®) in detecting SARS‐CoV‐2 in NP VTM and saline, nasal, and OP swabs. Conversely, saliva testing on the Cepheid showed statistically significant lower sensitivity compared to the BioFire(®). Finally, NP swabs in saline showed no significant difference compared with NP swabs in VTM on both platforms. CONCLUSION: The Cepheid and BioFire(®) NGDS are viable options to address a variety of public health needs providing rapid and reliable, point‐of‐care testing using a variety of clinical matrices. In late 2019, a novel respiratory pathogen appeared in Wuhan city, Hubei province, China with symptoms resembling both influenza and pneumonia. 1, 2 Initial sequencing determined that the etiological respiratory agent was a new virus of the genus Betacoronavirus, within the family Coronaviridae, 3 To overcome supply chain obstacles and improve turnaround times, many healthcare systems including the military began relying on the use of next generation diagnostic systems (NGDS) for infectious disease testing and surveillance. A significant benefit from the use of these systems is the reduced use of reagents and samples due to the integrated sample processing. Within the military health system (MHS), two NGDS have been previously used for the detection of upper respiratory pathogens and are currently used for SARS-CoV-2: the BioFire ® FilmArray ® 2.0 and Cepheid GeneXpert ® . The BioFire ® FilmArray ® 2.0 system uses the FimArray ® Respiratory The purpose of the current study was to 1) determine whether the BioFire ® FilmArray ® RP 2.1 and Cepheid Xpert ® SARS-CoV-2\ Flu\RSV assays were comparable at detecting SARS-CoV-2 in clinical upper respiratory tract samples, 2) perform an independent validation of their limit of detection of these assays, and 3) assess clinical sample concordance as specified by their respective EUAs. Additionally, BioFire ® RP2.1 and Cepheid SARS-CoV-2/Flu/RSV panels were used to compare four upper respiratory biospecimen collection sites as well as the use of saline as an alternative transport medium to the previously validated nasopharyngeal (NP) swab in VTM. Previously identified SARS-CoV-2 negative samples were pooled and tested by RT-PCR. After confirmation of negativity, samples were spiked with known concentrations of SARS-CoV-2 viral RNA. Concentrations ranged from 50 to 150 copies/ml for the Cepheid Xpert ® SARS-CoV-2/Flu/RSV assay and 150-500 copies/ml for the RP2.1 testing. (Table 1) . A sample is considered positive for SARS-CoV-2 when either one or both proteins are detected. According to the IFU provided by the manufacturer as part of the EUA approval, the RP2.1 positive percent agreement (PPA) was determined to be 98% and the negative percent agreement (NPA) was 100% in archived specimens. Similarly, the Cepheid GeneXpert ® Xpert ® SARS-CoV-2/Flu/ RSV assay (Cepheid) is fully automated and based on cartridge technology with all the reagents on-board for a completely handsoff workflow that integrates sample preparation, nucleic acid extraction, amplification, and detection of respiratory viruses in nasopharyngeal, mid-turbinate, and nasal swabs. Unlike the RP2.1, the Xpert ® SARS-CoV-2/Flu/RSV assay can only simultaneously detect three common upper respiratory pathogens (influenza A, B, and respiratory syncytial virus) in addition to SARS-CoV-2. The specific integrated primers for SARS-CoV-2 proteins target the nucleocapsid (N) and the envelope protein (E) ( Table 1 ). The EUA IFU for Xpert ® SARS-CoV-2/Flu/RSV assay states a PPA of 97.9% and a NPA of 100.0% in archived samples. Differences in SARS-CoV-2 detection between the two transport media types (VTM and saline) used for NP swabs were determined. A regression analysis was conducted to compare the cycle threshold (C t ) values from NP swabs diluted in VTM to NP swabs diluted in saline. The comparative analysis was limited to SARS-CoV-2 positive samples detected by the Cepheid Xpert ® SARS-CoV-2/Flu/ RSV assay because SARS-CoV-2 negative samples and BioFire ® FilmArray ® system do not produce a C t value. Given that saliva had not been validated as a sample type for SARS-CoV-2 detection by either the Cepheid or BioFire ® assays at the time of our testing and is known to contain cellular debris, we evaluated whether sample centrifugation to remove cellular debris reduced SARS-CoV-2 detection. C t values from saliva samples evaluated before centrifugation were compared to those obtained from identical samples which were not centrifuged. Statistical analyses were performed using R version 4.0.3 and the R packages "epiR" and "fmsb." For comparative analyses between platforms and between sample types, we used Cohen's kappa statistics to estimate agreement and test the null hypothesis that agreement was random (i.e., kappa statistic equals zero). 7 McNemar's chisquare test was used to test the null hypothesis that the platforms are equivalent in terms of sensitivity and specificity. 8 As a result of the recruitment plan for this study, there was a time lag between initial RT-PCR Clinical Laboratory Improvement concordant positive samples and discordant samples which were positive on the Cepheid, but negative on the BioFire ® . We encoded "detected" and "not detected" as 1 and 0, respectively, and used locally weighted scatterplot smoothing implemented within the loss. Smooth R function with an alpha of 0.1 to visually evaluate the relationship between the percentage of samples that tested positive and the length of time that passed between positive CLIA testing and sample collection. Linear regression and visual interpretation of scatter plots were used to understand the relationship between C t values before and after centrifugation of saliva samples. A paired t test was used to test the null hypothesis of no difference in the mean C t values before and after centrifugation. iSpecimen, Inc. recruited and consented 216 study participants between November 6, 2020, and January 7, 2021, at three sites located in California, New Jersey, and New York. Each study participant provided nasal and OP swabs, two NP swabs, and a saliva sample. For the evaluation of the effects of transport media on SARS-CoV-2 detection, the two NP swabs were stored and transported in either VTM or saline, individually. The age and sex information for the study participants is shown in Table 2 . Initial testing using saliva samples led to the qualitative observation that the Cepheid platform was detecting fewer SARS-CoV-2 positive samples compared with the BioFire ® . It was hypothesized that cellular debris in saliva samples was interfering with the performance of this platform. To test this hypothesis, saliva samples used for the Cepheid were briefly centrifuged to sediment cellular debris and reanalyzed. As shown in Figure 3 C t values of SARS-CoV-2 detection from Cepheid were strongly correlated before and after centrifuga- The initial shortages in VTM availability at the beginning of the pandemic highlighted the need to validate additional transport matrices. Thus, we compared SARS-CoV-2 detection in NP swabs stored and transported in either VTM or saline. On the Xpert ® SARS-CoV-2/ Flu/RSV assay, Kappa statistic (k = 0.82) indicated "nearly perfect agreement" between nasopharyngeal samples stored and transported in saline and VTM ( between NP swabs diluted in VTM and Saline (Table 5 ). The current study demonstrates the utility of using upper respiratory tract specimen types other than NP swabs in VTM, the gold standard, as well as NGDS to accurately and quickly detect SARS-CoV-2. Early on in the pandemic, testing procedures relied only on the use of NP swabs transported in VTM. 9 As NP collection is inherently uncomfortable it may be likely to deter some individuals from being tested. 9 Therefore, the validation of additional upper respiratory specimens could circumvent the need for healthcare workers to rely solely on NP swabs in VTM, not only overcoming patient hesitancy but also future supply shortages. Results from both the BioFire ® RP2.1 and Cepheid Xpert ® SARS-CoV-2/Flu/RSV assays, using specimen types not currently validated for testing such as nasal swabs, OP swabs, and saliva yield estimates for PPA and PNA that ranged between 70% and 100%. These estimates provide evidence that alternative respiratory sample matrices can serve as acceptable candidate specimens for SARS-CoV-2 testing. Additionally, given that some VTM formulations have been reported to yield false negative results we addressed the practicality of using saline as an alternative medium to transport NP swabs. 10, 11 We found no difference in SARS-CoV-2 detection in NP swabs transported in either saline or VTM. We observed a high positive and negative concordance between the two transport matrices suggesting that both media types are equally viable options for collection of nasopharyngeal samples for SARS-CoV-2 testing. We also evaluated the utility of using saliva as a suitable sample type for diagnostic testing of individuals experiencing symptoms of COVID-19. One impediment to the use of saliva for clinical testing is the additional centrifugation step may prove difficult or unsuitable in rural testing sites, at home, or in austere environments. Nagura-Ikeda et al suggested that results using saliva can be highly variable and that better processing techniques may improve testing sensitivity. 12 As such, we wanted to determine whether the centrifugation of cellular debris increased the detectability of SARS-CoV-2 in clinical samples as has been reported by others. 13 Interestingly, our data showed no significant difference when using saliva samples with and without a centrifugation step prior to testing. Our results support previous studies proposing saliva as a candidate clinical specimen for the detection of SARS-CoV-2. 14,15 One limitation of this study is that biological samples were not The COVID-19 pandemic altered how the world reacts to a highly transmissible RNA virus, including producing highly effective deployable, diagnostic tests to help curb spread of the novel virus. This study has shown that both the BioFire ® FilmArray ® RP2.1 and Cepheid Xpert ® Xpress SARS-CoV-2/Flu/RSV assays serve as ideal candidates for rapid testing and reliable detection of SARS-CoV-2 in a variety of clinical matrices. The authors have nothing to disclose. Note: Transport media does not affect SARS-CoV-2 detection in nasopharyngeal swabs. Nasopharyngeal swabs were diluted in either VTM or saline and were tested on the BioFire ® RP2.1 and Cepheid Xpert ® SARS-CoV-2/Flu/RSV assays. Abbreviations: NPA, negative percent agreement; PPA, positive percent agreement; RP2.1, respiratory panel 2.1; VTM, viral transport media. A pneumonia outbreak associated with a new coronavirus of probable bat origin A novel coronavirus from patients with pneumonia in China Severe acute respiratory syndrome-related coronavirus: the species and its viruses -a statement of the Coronavirus Study Group Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2 Key actions to advance development of novel coronavirus medical countermeasures Policy for coronavirus disease-2019 tests during the public health emergency (Revised) [press release The measurement of observer agreement for categorical data investr: an R package for inverse estimation How to perform a nasopharyngeal swab in adults and children in the COVID-19 era The impact of viral transport media on PCR assay results for the detection of nucleic acid from SARS-CoV-2 Influence of storage conditions on SARS-CoV-2 nucleic acid detection in throat swabs Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19 Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/ COVID-19 detection Saliva exhibits high sensitivity and specificity for the detection of SARS-COV-2 Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study Comparison of next generation diagnostic systems (NGDS) for the detection of SARS-CoV-2